• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Charming Medical Limited

    10/28/25 5:20:01 PM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MCTA alert in real time by email
    6-K 1 ea0262769-6k_charming.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of October 2025

     

    Commission File Number: 001-42907

     

    Charming Medical Limited

     

    Units 1803-1806, 18/F, Hang Lung Centre
    2-20 Paterson Street, Causeway Bay, Hong Kong

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

    On October 24, 2025, Cathay Securities, Inc., as the representative (the “Representative”) of the underwriters in the initial public offering of Charming Medical Limited (the “Company”), exercised in full its over-allotment option (the “Over-Allotment Option”) to purchase an additional 240,000 Class A ordinary shares, par value $0.0001 per share, of the Company (the “Additional Shares”) at the public offering price of US$4.00 per share. The closing of the sale of the Additional Shares took place on October 28, 2025.

     

    The Company received gross proceeds of US$960,000 from the full exercise of the Over-Allotment Option, before deducting underwriting discounts and other related expenses. As a result, the total gross proceeds to the Company’s from its initial public offering, including the Over-Allotment Option, were approximately US$7.36 million, before deducting underwriting discounts and other related expenses.

     

    A copy of the press release announcing the full exercise of the Over-Allotment Option is attached as Exhibit 99.1 and incorporated herein by reference. This report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Charming Medical Limited
         
    Date: October 28, 2025 By: /s/ Kit Wong
      Name: Kit Wong
      Title: Chief Executive Officer and Chairman of the Board

     

    2

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Press release dated October 28, 2025, announcing the full exercise of the Over-Allotment Option

     

    3

     

    Get the next $MCTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MCTA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MCTA
    SEC Filings

    View All

    SEC Form 6-K filed by Charming Medical Limited

    6-K - Charming Medical Ltd (0002035992) (Filer)

    11/13/25 6:01:23 AM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Charming Medical Limited

    6-K - Charming Medical Ltd (0002035992) (Filer)

    10/28/25 5:20:01 PM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care

    $MCTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nasdaq Halts Charming Medical Limited

    NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) --  The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading is halted in Charming Medical Limited (NASDAQ:MCTA) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in MCTA from 04:00:00 on November 12, 2025 to 23:59:00 on November 25, 2025. The last sale price of the company's ordinary shares was $29.355.  More information about the SEC's order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104176.pdf. Trading will remain halted until Charming Medical Limited has fully satisfied Nasdaq's request for additional information. For news

    11/26/25 7:00:00 AM ET
    $MCTA
    $NDAQ
    Misc Health and Biotechnology Services
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option

    HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Charming Medical Limited (NASDAQ:MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering") of 1,600,000 Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares") at a price of $4.00 per share (the "Public Offering Price"), Cathay Securities, Inc., the representative of the underwriters (the "Representative") of the Offering, has exercised its over-allotment option (the "Over-allotment") in full to purchase an additional 240,000 Class A Ordinary Shares at the Publ

    10/28/25 4:15:00 PM ET
    $MCTA
    Misc Health and Biotechnology Services
    Health Care